Franklin Street Advisors’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-8,000
| Closed | -$62K | – | 171 |
|
|
2025
Q1 | $62K | Hold |
8,000
| – | – | ﹤0.01% | 160 |
|
|
2024
Q4 | $106K | Buy |
8,000
+4,000
| +100% | +$37.2K | 0.01% | 161 |
|
|
2024
Q3 | $40K | Hold |
4,000
| – | – | ﹤0.01% | 162 |
|
|
2024
Q2 | $89K | Buy |
+4,000
| New | +$124K | 0.01% | 167 |
|
|
2023
Q2 | – | Sell |
-400
| Closed | -$187K | – | 154 |
|
|
2023
Q1 | $187K | Hold |
400
| – | – | 0.02% | 140 |
|
|
2022
Q4 | $160K | Buy |
+400
| New | +$153K | 0.02% | 139 |
|
|
2022
Q2 | – | Sell |
-800
| Closed | -$240K | – | 153 |
|
|
2022
Q1 | $240K | Sell |
800
-40
| -5% | -$13.9K | 0.02% | 141 |
|
|
2021
Q4 | $296K | Buy |
840
+40
| +5% | +$12.5K | 0.02% | 131 |
|
|
2021
Q3 | $204K | Hold |
800
| – | – | 0.02% | 151 |
|
|
2021
Q2 | $533K | Buy |
800
+400
| +100% | +$230K | 0.05% | 107 |
|
|
2021
Q1 | $347K | Hold |
400
| – | – | 0.03% | 118 |
|
|
2020
Q4 | $371K | Hold |
400
| – | – | 0.04% | 117 |
|
|
2020
Q3 | $411K | Hold |
400
| – | – | 0.04% | 106 |
|
|
2020
Q2 | $405K | Hold |
400
| – | – | 0.05% | 100 |
|
|
2020
Q1 | $348K | Hold |
400
| – | – | 0.05% | 100 |
|
|
2019
Q4 | $429K | Hold |
400
| – | – | 0.05% | 107 |
|
|
2019
Q3 | $370K | Hold |
400
| – | – | 0.05% | 112 |
|
|
2019
Q2 | $452K | Hold |
400
| – | – | 0.06% | 108 |
|
|
2019
Q1 | $544K | Hold |
400
| – | – | 0.08% | 101 |
|
|
2018
Q4 | $463K | Hold |
400
| – | – | 0.07% | 98 |
|
|
2018
Q3 | $608K | Hold |
400
| – | – | 0.08% | 90 |
|
|
2018
Q2 | $626K | Hold |
400
| – | – | 0.09% | 90 |
|
|
2018
Q1 | $462K | Hold |
400
| – | – | 0.07% | 99 |
|
|
2017
Q4 | $474K | Hold |
400
| – | – | 0.07% | 108 |
|
|
2017
Q3 | $538K | Hold |
400
| – | – | 0.09% | 97 |
|
|
2017
Q2 | $323K | Hold |
400
| – | – | 0.06% | 117 |
|
|
2017
Q1 | $247K | Sell |
400
-800
| -67% | -$487K | 0.04% | 141 |
|
|
2016
Q4 | $642K | Hold |
1,200
| – | – | 0.11% | 113 |
|
|
2016
Q3 | $621K | Hold |
1,200
| – | – | 0.11% | 119 |
|
|
2016
Q2 | $492K | Hold |
1,200
| – | – | 0.09% | 130 |
|
|
2016
Q1 | $639K | Buy |
1,200
+400
| +50% | +$199K | 0.13% | 126 |
|
|
2015
Q4 | $609K | Hold |
800
| – | – | 0.12% | 131 |
|
|
2015
Q3 | $438K | Hold |
800
| – | – | 0.09% | 146 |
|
|
2015
Q2 | $470K | Buy |
+800
| New | +$465K | 0.08% | 147 |
|
Other funds holding KYNB
AC
CCM
Franklin Street Advisors's KYNB Position: Q2 2025 in Review
Franklin Street Advisors sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 8,000 shares — an estimated $62K sold.
Franklin Street Advisors first reported a position in KYNB in Q2 2015 and held it in 34 quarters. The position peaked at $642K in Q4 2016. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.
- Franklin Street Advisors reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
- Franklin Street Advisors sold 8,000 Kyntra Bio shares in Q2 2025, an estimated $62K.
- Franklin Street Advisors first reported a position in Kyntra Bio in Q2 2015 and held it in 34 quarters.
- Franklin Street Advisors's Kyntra Bio position peaked at $642K in Q4 2016.
- 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.
Based on Franklin Street Advisors's 13F filing for Q2 2025, filed 21 Jul 2025.